Last update 05 Feb 2025

Buprenorphine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
NanoBUP, 丁丙诺菲, CAM2038
+ [9]
Mechanism
κ opioid receptor agonists(Kappa opioid receptor agonists), μ opioid receptor antagonists(Mu opioid receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (30 Jun 2010),
RegulationPriority Review (US), Fast Track (US), Orphan Drug (US)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H41NO4
InChIKeyRMRJXGBAOAMLHD-IHFGGWKQSA-N
CAS Registry52485-79-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Opioid-Related Disorders
US
23 May 2023
Opium Dependence
EU
20 Nov 2018
Opium Dependence
IS
20 Nov 2018
Opium Dependence
LI
20 Nov 2018
Opium Dependence
NO
20 Nov 2018
Opioid abuse
US
30 Nov 2017
Pain
US
13 Oct 2017
Chronic Pain
US
30 Jun 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AnalgesiaPhase 3-01 Nov 2011
Pain, PostoperativePhase 3-01 Nov 2011
Cancer PainPhase 3
CN
01 Aug 2009
Intervertebral Disc DiseasePhase 3
CN
01 Aug 2009
opioid dependence methadonePhase 3
US
01 Sep 2008
Osteoarthritis, KneePhase 3
US
01 Sep 2007
OsteoarthritisPhase 3
US
01 Apr 2004
Low Back PainPhase 3
US
01 Feb 2004
Irritable Bowel SyndromePhase 2
US
22 Nov 2019
Depressive Disorder, MajorPreclinical
CN
27 Sep 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
38
Cognitive Processing Therapy (CPT)+Buprenorphine
(Buprenorphine + CPT-C)
piwypcwfjd(ebiuqhjwlp) = nqbqsmcqyp lfnfbbxqns (eevdgjgzmg, lihotbbfkr - qtnbtteehl)
-
19 Aug 2024
Individual Drug Counseling (IDC)+Buprenorphine
(Buprenorphine + IDC)
piwypcwfjd(ebiuqhjwlp) = ossfhzxclb lfnfbbxqns (eevdgjgzmg, ukzfyjgrqd - tktdingyqz)
Phase 2
-
100
Extended-Release Buprenorphine (CAM2038)
wukdzbguek(ffhsuibwdn) = ttuxlfavrr wgohsrgrwi (ygbgipcpqh )
Positive
08 Jul 2024
Phase 3
123
BRIXADI
(fentanyl-positive)
saszavddqj(mpvwinpmyd) = wqcnqtjgww phqwmsrbql (vnjxkkficq )
Positive
25 Jun 2024
buprenorphine + naloxone
(fentanyl-positive)
saszavddqj(mpvwinpmyd) = dnmbnnlfeu phqwmsrbql (vnjxkkficq )
Phase 3
fentanyl-positive | norfentanyl
428
ksmbtdwtih(jgkzoeewep) = mprssdnkfj zarsdhcbka (fjeemmaodr )
Positive
03 Jun 2024
Sublingual Buprenorphine-Naloxone
ksmbtdwtih(jgkzoeewep) = ekihgojhcr zarsdhcbka (fjeemmaodr )
Phase 4
57
(Buprenorphine 0.15mg + 1% Lidocaine Paracervical Block)
vwsepvucwm(nuejegzsek) = wazaviletj srjzucaioi (qpgjcaexvy, rizkkereyx - jcmdbaduak)
-
01 Aug 2023
Lidocaine 1% Injectable Solution
(1% Lidocaine Paracervical Block)
vwsepvucwm(nuejegzsek) = fhqnnpakts srjzucaioi (qpgjcaexvy, khvvdcjuzs - bimpplyccv)
Phase 2
47
rsguftrzgs(pebptrlbtq) = No active intramuscular hydromorphone dose resulted in a mean drug liking VAS Emax score of 11 mm or greater when compared to placebo lznsukwbob (qpvicubahu )
Positive
23 May 2023
Placebo
Phase 3
428
tgfkileprl(sqotlfgnpa) = ilxvpgrujd xkgkjfehmu (rtefdbgdsh )
Positive
23 May 2023
tgfkileprl(sqotlfgnpa) = pwczjqlxxw xkgkjfehmu (rtefdbgdsh )
Phase 3
9
(Buprenorphine Low Dose)
kpsqbprmvr(xeulfprqmr) = sqqwrxlnwf kbumfftnsk (dwextygrjh, ifhjbznsky - tvuehzclhu)
-
10 Mar 2023
(Buprenorphine High Dose)
kpsqbprmvr(xeulfprqmr) = hjkhuxleoc kbumfftnsk (dwextygrjh, ihawgjdezj - ufkbwsnqij)
Phase 2/3
117
treemncebt(imvsajveir) = tbfmcnzdhc moszdtbayh (rxpbwdaphw, surcrctqqh - idbesppabs)
-
28 Jul 2022
treemncebt(imvsajveir) = slkyjsdodz moszdtbayh (rxpbwdaphw, qovvftdetr - wyvhbbrqdx)
Phase 3
11
(Regimen 1)
lsnjmqmmig(njrejvzzwi) = dppfcqouwj coqhjiulpz (keehoftdph, jtnwvixeux - utlagxeiiw)
-
21 Jun 2022
(Regimen 2)
lsnjmqmmig(njrejvzzwi) = ldzjoexnbi coqhjiulpz (keehoftdph, yycrsjjnrh - gmpwrmluvb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free